Fast-track diagnosis for Giant Cell Arteritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on improving the diagnosis of Giant Cell Arteritis (GCA), a serious condition that can lead to vision loss or stroke if not identified quickly. It leverages advanced ultrasound techniques to detect inflammation in the temporal arteries, potentially eliminating the need for invasive biopsies in patients with high clinical suspicion of GCA. The study aims to validate the effectiveness of a fast-track diagnostic pathway based on ultrasound findings. By streamlining the diagnostic process, the study seeks to enhance patient outcomes through timely intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient suspected of GCA

Exclusion Criteria:

* Opposition to the use of their data

Where it's running

• Groupe Hospitalier de la Rochelle Ré Aunis
  La Rochelle, France Recruiting

Study contacts

• Study coordinator: Caroline Allix-Béguec, Ph.D.
• Email: caroline.allix-beguec@ght-atlantique17.fr
• Phone: +33516494246

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Giant Cell Arteritis: Monitoring Disease Activity and Relapse Risk in Remission

  This study tests tools that help monitor disease activity and predict relapses in people with giant cell arteritis who are in remission.

  Recruiting at 4 sites University of Aarhus · Aalborg and 6 other locations · NCT07552636

• Combining vascular ultrasound and blood markers to improve diagnosis and monitoring of giant cell arteritis

  This project will test whether adding extended ultrasound scans to new blood biomarkers can better predict relapse and tell active from inactive giant cell arteritis in people referred for suspected GCA.

  Recruiting Vastra Gotaland Region · Gothenburg · NCT07246577

• Orbital blood-vessel inflammation in giant cell arteritis and ischemic optic neuropathy

  This project will test whether advanced FDG PET/MRI with black-blood sequences plus OCT scans can tell if sudden optic nerve damage is due to giant cell arteritis or non-arteritic ischemic optic neuropathy in people aged 50 and older.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Glostrup Municipality · NCT07206238

• Personalized lab test to predict the best treatment for rheumatic diseases

  This project tests a lab-based cell assay to see if it can predict which DMARD will work best for adults with autoimmune rheumatic diseases such as RA, PsA, axSpA, and GCA.

  Recruiting University of Bonn · Bonn, North Rhine-Westphalia · NCT07150000

• Stopping versus reducing tocilizumab for people with well-controlled giant cell arteritis

  This trial will test whether stopping tocilizumab or reducing its dose better maintains remission in people with giant cell arteritis who have been on high-dose tocilizumab for at least 12 months and off steroids for at least three months.

  Recruiting at 7 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Atlanta, Georgia and 6 other locations · NCT07108387

• Halo sign in GCA: how soon after steroids to perform Doppler ultrasound

  This study tests whether timing of Doppler ultrasound after starting steroids affects the ability to see the halo sign in adults with giant cell arteritis.

  Recruiting at 4 sites Centre Hospitalier le Mans · Le Mans, Sarthe and 5 other locations · NCT07060274

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.